{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:31:02Z","timestamp":1790627462941,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T00:00:00Z","timestamp":1388707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s40258-013-0072-7","type":"journal-article","created":{"date-parts":[[2014,1,2]],"date-time":"2014-01-02T12:15:56Z","timestamp":1388664956000},"page":"85-93","source":"Crossref","is-referenced-by-count":13,"title":["Budget Impact Analysis of Liposomal Amphotericin B and Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections in the United States"],"prefix":"10.1007","volume":"12","author":[{"given":"Hongbo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paresh","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Q.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,3]]},"reference":[{"issue":"19","key":"72_CR1","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2146\/ajhp080325","volume":"66","author":"J Menzin","year":"2009","unstructured":"Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm. 2009;66(19):1711\u20137.","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"72_CR2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/514955","volume":"27","author":"AM Rentz","year":"1998","unstructured":"Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis. 1998;27(4):781\u20138.","journal-title":"Clin Infect Dis"},{"issue":"Pt 7","key":"72_CR3","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1099\/jmm.0.46548-0","volume":"55","author":"DA Enoch","year":"2006","unstructured":"Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol. 2006;55(Pt 7):809\u201318.","journal-title":"J Med Microbiol"},{"key":"72_CR4","doi-asserted-by":"crossref","unstructured":"Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (Prospective Antifungal Therapy) Alliance(R) registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73(4):293\u2013300.","DOI":"10.1016\/j.diagmicrobio.2012.06.012"},{"issue":"3","key":"72_CR5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0924-8579(00)00341-1","volume":"17","author":"IM Hann","year":"2001","unstructured":"Hann IM, Prentice HG. Lipid-based amphotericin B: a review of the last 10\u00a0years of use. Int J Antimicrob Agents. 2001;17(3):161\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"72_CR6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","volume":"98","author":"HG Prentice","year":"1997","unstructured":"Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98(3):711\u20138.","journal-title":"Br J Haematol"},{"issue":"1","key":"72_CR7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","volume":"103","author":"AC Leenders","year":"1998","unstructured":"Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998;103(1):205\u201312.","journal-title":"Br J Haematol"},{"issue":"5","key":"72_CR8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0609.2004.00239.x","volume":"72","author":"M Subira","year":"2004","unstructured":"Subira M, Martino R, Gomez L, Marti JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies\u2014a randomized, controlled trial. Eur J Haematol. 2004;72(5):342\u20137.","journal-title":"Eur J Haematol"},{"issue":"1","key":"72_CR9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1046\/j.1365-2141.1998.00934.x","volume":"103","author":"AD Clark","year":"1998","unstructured":"Clark AD, McKendrick S, Tansey PJ, Franklin IM, Chopra R. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol. 1998;103(1):198\u2013204.","journal-title":"Br J Haematol"},{"issue":"5","key":"72_CR10","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","volume":"31","author":"JR Wingard","year":"2000","unstructured":"Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group. Clin Infect Dis. 2000;31(5):1155\u201363.","journal-title":"Clin Infect Dis"},{"issue":"5\u20136","key":"72_CR11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/10428190109097650","volume":"40","author":"RV Fleming","year":"2001","unstructured":"Fleming RV, Kantarjian HM, Husni R, Rolston K, Lim J, Raad I, et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma. 2001;40(5\u20136):511\u201320.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"72_CR12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.11936","volume":"100","author":"GN Mattiuzzi","year":"2004","unstructured":"Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004;100(3):581\u20139.","journal-title":"Cancer"},{"issue":"6","key":"72_CR13","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/cncr.23311","volume":"112","author":"RY Hachem","year":"2008","unstructured":"Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer. 2008;112(6):1282\u20137.","journal-title":"Cancer"},{"issue":"4","key":"72_CR14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MD.0b013e3181e9441b","volume":"89","author":"A Safdar","year":"2010","unstructured":"Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore). 2010;89(4):236\u201344.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"72_CR15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.diagmicrobio.2013.04.001","volume":"76","author":"RL Wade","year":"2013","unstructured":"Wade RL, Chaudhari P, Natoli JL, Taylor RJ, Nathanson BH, Horn DL. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex. Diagn Microbiol Infect Dis. 2013;76(3):361\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"72_CR16","unstructured":"Bureau of Labor Statistics. Consumer price index\u2014all urban consumers. http:\/\/www.bls.gov\/cpi\/ . Cited 24 Jan 2012."},{"key":"72_CR17","unstructured":"CMS Medicare Part B Drug Average Sales Price. https:\/\/www.cms.gov\/McrPartBDrugAvgSalesPrice\/01a17_2012ASPFiles.asp . Cited 24 Jan 2012."},{"issue":"1\u20134","key":"72_CR18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3111\/200205109118","volume":"5","author":"RN Greenberg","year":"2002","unstructured":"Greenberg RN, Cagnoni PJ, Wingard JR, Prendergast MM, Tong KB. Factors associated with increased hospital costs in patients treated with lipid-based amphotericin B for empirical therapy. J Med Econ. 2002;5(1\u20134):109\u201318.","journal-title":"J Med Econ"},{"key":"72_CR19","unstructured":"HCUPnet: a tool for identifying, tracking, and analyzing national hospital statistics. http:\/\/hcupnet.ahrq.gov\/HCUPnet.jsp . Cited 24 Jan 2012."},{"issue":"6","key":"72_CR20","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1185\/03007990802124889","volume":"24","author":"OA Cornely","year":"2008","unstructured":"Cornely OA, Sidhu M, Odeyemi I, van Engen AK, van der Waal JM, Schoeman O. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin. 2008;24(6):1743\u201353.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"72_CR21","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1200\/JCO.2000.18.12.2476","volume":"18","author":"PJ Cagnoni","year":"2000","unstructured":"Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol. 2000;18(12):2476\u201383.","journal-title":"J Clin Oncol"},{"issue":"6","key":"72_CR22","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1600-0609.2007.00850.x","volume":"78","author":"K Bruynesteyn","year":"2007","unstructured":"Bruynesteyn K, Gant V, McKenzie C, Pagliuca T, Poynton C, Kumar RN, et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol. 2007;78(6):532\u20139.","journal-title":"Eur J Haematol"},{"issue":"5","key":"72_CR23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/00019053-200422050-00004","volume":"22","author":"JL Kuti","year":"2004","unstructured":"Kuti JL, Kotapati S, Williams P, Capitano B, Nightingale CH, Nicolau DP. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics. 2004;22(5):301\u201310.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"72_CR24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1524-4733.2002.51108.x","volume":"5","author":"LS Wilson","year":"2002","unstructured":"Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health. 2002;5(1):26\u201334.","journal-title":"Value Health"},{"issue":"4","key":"72_CR25","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1046\/j.1365-2141.1998.0952a.x","volume":"102","author":"P Schneider","year":"1998","unstructured":"Schneider P, Klein RM, Dietze L, S\u00f6hngen D, Leschke M, Heyll A. Anaphylactic reaction to liposomal amphotericin (AmBisome). Br J Haematol. 1998;102(4):1108\u20139.","journal-title":"Br J Haematol"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-013-0072-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-013-0072-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-013-0072-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T18:23:14Z","timestamp":1565029394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-013-0072-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,3]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["72"],"URL":"https:\/\/doi.org\/10.1007\/s40258-013-0072-7","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,3]]}}}